Ladan Zand
@LadanZand
Nephrologist. Interested in GN.
Doughnuts again (just because they were so good the first time) - banana bread and lemon cupcakes from a few weeks ago that I forgot to post!
Thrilled to see our work — developed during my time at the @MayoClinic — now published 📢Grateful for the opportunity to contribute to such a stimulating academic environment 📚 #MedicalResearch #AcademicPublishing #MayoClinic #Nephrology
I am excited to share our latest paper on the potential association between monoclonal gammopathy and ANCA negative vasculitis. Monoclonal testing should be considered in ANCA negative patients. @mvargas07 @fervenzafernan1 journals.lww.com/kidney360/abst…
I am excited to share our latest paper on the potential association between monoclonal gammopathy and ANCA negative vasculitis. Monoclonal testing should be considered in ANCA negative patients. @mvargas07 @fervenzafernan1 journals.lww.com/kidney360/abst…
All what you need to know about MN....."Antigens in membranous nephropathy: discovery and clinical implications" | Nature Reviews Nephrology @SethiRenalPath @fervenzafernan1 @MayoClinicNeph @MayoTransplant nature.com/articles/s4158…
Clinical trial at our Mayo Clinic Nephrology: Evaluating daratumumab for treatment of PGNMID (Proliferative Glomerulonephritis with Monoclonal Immune Deposits). A novel approach to a rare glomerular disease. @fervenzafernan1 @LadanZand Learn More🔗 mayo.edu/research/clini…
𝐈𝐬 𝐒𝐄𝐗 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐢𝐧 𝐀𝐍𝐂𝐀 𝐯𝐚𝐬𝐜𝐮𝐥𝐢𝐭𝐢𝐬?? @MayoClinicNeph @NefrologiaVH @vallhebron work. Truly indebted to @martacasalmoura & @fervenzafernan1 for the opportunity to work on this project. @womeninnephro @ISNkidneycare @SENefrologia @senjoven @isciii
Sex-specific clinical presentations and outcomes in ANCA vasculitis presenting with severe kidney disease doi.org/10.1093/ndt/gf…
Do you have crescentic IgA Nephropathy? You may qualify for a Mayo Clinic clinical trial evaluating a novel treatment for crescentic IgAN. “Avacopan in Crescentic IgAN” Learn more and see if you are eligible: Link 🔗 mayo.edu/research/clini… @fervenzafernan1 @LadanZand
Clinical Phenotypes and Renal Outcomes in PLA2R-Associated Membranous Nephropathy: A Multi-Center Cohort Study with Unsupervised Cluster Analysis @LadanZand @jingmiao2019 @fervenzafernan1 @ShaneBobart @wisit661 @PepaSolerR @NDTsocial #AI #Nephrology academic.oup.com/ndt/advance-ar…
Mayo Clinic Laboratories' new mass spectrometry assay requires just one small tissue sample to identify 13 antigens known to cause membranous nephropathy. Learn more about this one-stop test. @SethiRenalPath bit.ly/4k1loks
🎥🎥🎥 “𝟏𝐫𝐬𝐭 𝐌𝐚𝐲𝐨 𝐂𝐥𝐢𝐧𝐢𝐜 - 𝐕𝐚𝐥𝐥 𝐝’𝐇𝐞𝐛𝐫𝐨𝐧 𝐍𝐄𝐏𝐇𝐑𝐎𝐋𝐎𝐆𝐘 𝐔𝐏𝐃𝐀𝐓𝐄” 5-6 Sep Barcelona 2025. Register to [email protected] @MayoClinicNeph @NefrologiaVH @vallhebron @HerrmannMd @OriolBestard @fervenzafernan1 @LadanZand #andreaKattah
In this multi-center study we describe 3 distinct phenotypes of patients with PLA2R-MN using unsupervised machine learning! @jingmiao2019 @fervenzafernan1 @ShaneBobart @wisit661 @PepaSolerR @NDTsocial academic.oup.com/ndt/advance-ar…
🎥🎥🎥 “𝟏𝐫𝐬𝐭 𝐌𝐚𝐲𝐨 𝐂𝐥𝐢𝐧𝐢𝐜 - 𝐕𝐚𝐥𝐥 𝐝’𝐇𝐞𝐛𝐫𝐨𝐧 𝐍𝐄𝐏𝐇𝐑𝐎𝐋𝐎𝐆𝐘 𝐔𝐏𝐃𝐀𝐓𝐄” save the dates 5-6 Sep Barcelona 2025. Register to [email protected] organized by @MayoClinicNeph @NefrologiaVH @vallhebron @HerrmannMd @OriolBestard @fervenzafernan1